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Cat Got Your Tongue?
To the Editor—A 69-year-old woman
with a history of seizures, which were well
controlled with sodium valproate, and de-
pression presented with acute onset of a
painful swollen tongue that resulted in
dysphagia, dysphonia, and drooling of sa-
liva. She had not begun treatment with
any new medications and was not using
an angiotensin-converting enzyme inhib-
itor. There was no history of recent dental
problems, and her only other medication
was dothiepin.
On examination, her temperature was
37.6C. There was gross swelling of the
floor of the mouth and tongue, with no
erythema. There was no exudate from the
submandibular gland duct. The epiglottis
and larynx were normal when visualized
by direct laryngoscopy. Her neck was
tender to palpation in the submental and
submandibular regions, but there was no
lymphadenopathy. There was no rash or
stridor, and chest auscultation revealed
normal vesicular breath sounds without
any wheeze. The patient was treated with
nebulized adrenaline, intravenous dexa-
methasone, and meropenem.
The C-reactive protein level was ele-
vated to 142 mg/L (normal, !6 mg/L), and
there was a neutrophilia with a marked
left shift. CT of the neck revealed some
patchy hypodensity in the inferior half of
the tongue, which was consistent with
edema/inflammatory change. Artifact
from amalgam fillings obscured the su-
perior half of the tongue. The salivary
glands had a normal appearance, and
there was no retropharyngeal or prever-
tebral collection. The nasopharynx, oro-
pharynx, and laryngopharynx were patent,
with no airway compromise.
Two sets of blood culture samples taken
at admission to the hospital grew Pasteu-
rella multocida. Subsequent history re-
vealed that the patient had a cat in her
home, but she could not recall a recent
bite or scratch. Antibiotic treatment was
changed to intravenous ampicillin and
then oral amoxycillin, and the patient
made a good recovery.
P. multocida is a small, gram-negative
coccobacillus that colonizes the naso-
pharnyx and gastrointestinal tracts of
many animals [1]. Most human P. mul-
tocida infections are caused by dog and cat
bites. These bites may result in various
clinical syndromes, including cellulitis,
subcutaneous abscesses, osteomyelitis,
septic arthritis, pneumonia, meningitis,
endocarditis, intra-abdominal infection,
and septicemia [1]. With regard to upper
respiratory tract infection, P multocida has
been associated with sinusitis, otitis media,
mastoiditis, tonsillitis, peritonsillar ab-
scess, and epiglottitis [1–3]. This is, to our
knowledge, the first reported case of P.
multocida bacteremia manifesting with
glossitis.
The earliest written example of the
phrase “cat got your tongue” in the Oxford
English Dictionary is from 1911; the ex-
pression is used when addressing someone
who is refusing to speak [4]. Several other
theories about the origins of this phrase
exist: (1) in the Middle East, liars, as pun-
ishment, had their tongues removed and
fed to the king’s cats; (2) during the Mid-
dle Ages, it was thought that, if you saw
a witch, her cat would steal or control your
tongue such that you could not report the
sighting; and (3) the fear of being whipped
by the cat o’nine tails would paralyze the
victim into silence [5].
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Warfarin and Efavirenz or
Lopinavir-Ritonavir in
Clinical Treatment
To the Editor—Warfarin undergoes
liver metabolism by CYP2C9 [1], which
is an isoenzyme of cytochrome P450
whose activity could be affected by anti-
retrovirals. The effect of coadministration
in HIV-positive patients has been reported
only for nevirapine, which has been shown
to decrease warfarin concentration, prob-
ably via CYP2C9 induction [2]; no clinical
data are yet available for other antiretro-
virals. We describe 2 cases concerning
coadministration of warfarin with efavi-
renz or lopinavir-ritonavir.
Case 1 occurred in a 34-year-old black
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woman who was receiving stable antiret-
roviral therapy with didanosine, lamivu-
dine, and efavirenz and who developed an
extensive deep vein thrombosis of the
right leg with involvement of inferior cave
and right iliac veins. The patient under-
went placement of a vena cava filter and
anticoagulant treatment. After 12 days, the
patient was discharged from the hospital
with a prescription for warfarin (mean
daily dose, 5 mg); she had an international
normalized ratio (INR) within the optimal
range (2–3) and a platelet count of 432,000
platelets/mL. The patient was readmitted
to the hospital 22 days after discharge be-
cause of macrohematuria associated with
an INR of 7, a platelet count of 58,000
platelets/mL, and normal renal function,
without clinical or other pharmacological
factors known to increase warfarin activity.
The patients most recent INR measure-
ment, obtained 3 days before, had shown
an INR of 2.7, and the patient denied over-
dosing. After admission, warfarin treat-
ment was transiently discontinued, vita-
min K supplementation was initiated,
bleeding rapidly ceased, and the patient’s
INR normalized. The patient’s 12-h efa-
virenz concentration in plasma was 3125
ng/mL. The patient was finally discharged
with a normalized platelet count and a
mean daily dose of warfarin of 1.25 mg
(one-fourth of the initial dose).
Case 2 occurred in a 66-year-old white
man who underwent mitral valve replace-
ment due to Streptococcus viridans endo-
carditis after stopping a previously effec-
tive HAART regimen that had included
zidovudine, lamivudine, and lopinavir-ri-
tonavir (400 mg/100 mg administered
twice per day). The patient was discharged
from the hospital with a warfarin daily
dose ranging between 3.75 mg and 5 mg
to maintain an INR within the optimal
range (2–3.5). Two months later, the pre-
vious HAART regimen was reintroduced.
After several days, a progressive increase
in warfarin dosing up to 10 mg daily was
needed to maintain an INR within the op-
timal range. Lopinavir plasma trough con-
centration was 4580 ng/mL. After 2 years,
when the patient’s treatment regimen was
simplified to zidovudine-lamivudine-aba-
cavir plus tenofovir, the warfarin dosage
was decreased to 3.75–5 mg daily.
These are, to our knowledge, the first
clinical reports on coadministration of
warfarin with efavirenz or lopinavir-rito-
navir. In both cases, the need for warfarin
dose adjustments was probably attribut-
able to the opposite effects of these 2 drugs
on CYP2C9.
Efavirenz was reported to be a moderate
inhibitor in vitro of such isoenzymes, po-
tentially increasing the levels and/or effects
of CYP2C9 substrates [3]. For instance,
efavirenz was shown to increase phenytoin
concentrations, because this anticonvul-
sant is known to be primarily metabolized
by CYP 2C9 and 2C19 [4]. In our case,
in which no explanations other than drug
interaction were found for the increase in
warfarin activity, the magnitude of inter-
action was impressive, leading to warfarin
overdosing. Although concomitant tran-
sient thrombocytemia (probably attrib-
utable to previous use of heparin) had
probably facilitated bleeding, a marked in-
crease in INR is, per se, considered to in-
dicate a high risk of hemorrhage [5].
Therefore, clinicians should be aware of
such possible occurrences in their patients.
On the other hand, ritonavir is known
to be an inducer of CYP2C9 [6]. The effect
of lopinavir-ritonavir (400 mg/100 mg
twice daily) on the metabolism of S-war-
farin (administered in a 10-mg single
dose) was studied in a group of 7 healthy
volunteers, resulting in a 22% decrease in
the warfarin area under the curve [7]. In
our patient, lopinavir-ritonavir treatment
was confirmed to decrease warfarin activ-
ity, but the magnitude of the interaction
was higher than expected, requiring a dou-
bling of the warfarin dose. This case high-
lights that data regarding drug interactions
obtained from single-dose studies involv-
ing healthy volunteers could not exactly
predict the extent of such interactions at
the steady-state concentration in patients.
In conclusion, the clinical cases re-
ported here showed clinically significant
drug interactions when efavirenz or lo-
pinavir-ritonavir were concomitantly ad-
ministered with warfarin, suggesting the
need for careful clinical monitoring and
warfarin dose adjustment.
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Figure 1. Representative PCR results showing amplification (or otherwise) of 298-bp genomic
fragment corresponding to IS900 in diabetic patients (lanes 1–8). Lanes 9 and 10, Control subjects
without type 1 diabetes mellitus. Lanes 11 and 12, Mycobacterium avium subspecies paratuber-
culosis–positive and M. avium subspecies paratuberculosis–negative control subjects, respectively.




Bacteremia in Type 1
Diabetes Mellitus:
An Infectious Trigger?
To the Editor—Mycobacterium avium
subspecies paratuberculosis (MAP) is the
established cause of paratuberculosis in
ruminants (i.e., Johne disease). The bac-
terium is shed in the milk of infected cows
and survives pasteurization. Recently, an
association between MAP and Crohn dis-
ease has been suggested, wherein MAP has
been found to persist in a cell wall–defi-
cient form, escaping clearance by the host
immune system [1, 2].
Type 1 (insulin-dependent) diabetes
mellitus (T1DM) reflects the interactions
of polygenic traits with ill-defined envi-
ronmental factors, and it is unknown what
initiates and maintains autoimmunity to
self-antigens expressed in the pancreatic
islets of Langerhans [3]. Consumption of
cow’s milk early in life has been a rec-
ognized risk factor in the development of
this disease, and environmental microor-
ganisms are thought to trigger autoim-
mune responses in genetically susceptible
individuals [4]. MAP bacilli have recently
been hypothesized to trigger molecular
mimicry and killing of pancreatic islet cells
by the immune system.
We attempted to test the association of
MAP with T1DM in an area of endemicity,
such as Sardinia, by testing patients with
T1DM for the presence of MAP bacilli in
peripheral blood. A total of 96 partici-
pants, composed of 46 patients with
T1DM and 50 healthy control subjects,
were tested for the presence of MAP-spe-
cific IS900 signature (figure 1) using total
DNA extracted from PBMCs. Informed
consent from patients, as well as other nec-
essary clearances, were procured before
blood samples were obtained. PCR was
performed to detect MAP DNA, as de-
scribed elsewhere [2]. IS900 fragment
identity was confirmed by sequencing
(GenBank accession group 1517012) and
by BLAST analysis against sequences in the
National Center for Biotechnology Infor-
mation database [5].
A total of 29 (63%) of 46 blood samples
from diabetic patients were found to be
positive for MAP, whereas only 8 (16%)
of the 50 samples from healthy control
subjects were positive for MAP. Although
a majority of diabetic patients with posi-
tive PCR results had a family history of
diabetes or other genetic and/or autoim-
mune disorders, 14 diabetic individuals
with positive PCR results did not have any
history of diabetes or other autoimmune
diseases in their families. Although the dif-
ferences in the outcome of PCR positivity
were statistically validated and found to be
significant ( ; ), it is our2x p 10.07 P .01
understanding that MAP-positive control
subjects might possibly be representing ei-
ther the genetic resistance or the asymp-
tomatic forms of variable duration that
generally precede the clinical presentation
of T1DM.
Genetic evidence suggests that there are
specific states of immune dysfunction that
promote both T1DM and mycobacterial
infection [6, 7]. Deficiency of vitamin D
has been implicated as a risk factor for
T1DM. Interestingly, vitamin D is also im-
plicated in limiting mycobacterial infec-
tion by upregulating expression of an an-
timicrobial peptide [8].
The island of Sardinia has a high inci-
dence of Crohn disease and other auto-
immune diseases, such as T1DM, with a
very high prevalence of MAP in Sardinian
patients with Crohn disease [2, 3]. Because
MAP is present in almost one-half of the
sheep herds tested in Sardinia, it is prob-
ably endemically contaminating water,
milk, and animal feed [9].
Finding evidence of MAP bacteremia in
patients with T1DM is a novel observation
that might provide an important foun-
dation in establishing an infectious etiol-
ogy for T1DM. These results also might
possibly have implications for countries
that have the greatest livestock popula-
tions and high incidence of MAP con-
current with the highest numbers of pa-
tients with T1DM. Although it is tempting
to suggest that MAP could be a potential
cause of autoimmune responses associated
with T1DM in Sardinia, we believe that a
large-scale study involving patients from
different genetic and geographic back-
grounds might further validate our
findings.
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To the Editor—Moore et al. [1] recently
described a significant difference in
CD4+ cell recovery following HIV RNA
suppression among patients receiving
HAART according to nadir CD4+ cell
count, with individuals whose nadir CD4+
cell counts were !200 cells/mL not achiev-
ing a protective CD4+ cell count.
A lack of CD4+ cell rescue despite com-
plete HAART-driven viremia suppression
represents an everyday dilemma for HIV/
AIDS clinicians [2]. Invariably, CD4+ cell
count nadir proved to be a major and re-
liable determinant of suboptimal CD4+
cell recovery and clinical outcome [1–8].
However, the mere quantification of CD4+
cell count nadir fails to qualitatively esti-
mate the ultimate immunological mech-
anism(s) hindering CD4+ cell rescue. Only
by detailing the immunological holes in
nadir-driven T cell homeostasis will it be
possible to devise the most efficacious
treatment approach.
By limiting immune recovery assess-
ment to total CD4+ cell count in a large
patient cohort, Moore et al. [1], although
gaining statistical power, miss an insight
into the immunological role of CD4+ cell
count nadir. On the contrary, we feel that
stringently focused studies are needed that
address the time course of specific im-
mune pathways by nadir CD4+ cell count
strata. It would be interesting to know
whether the authors have found distinct
dynamics in immunephenotype and other
immunologic parameters according to
CD4+ cell count ranges.
Given their major regulatory role in T
cell homeostasis, common g-chain cyto-
kines, including IL-2, IL-7, IL-15, and IL-
21 [9], might be ideal markers of the di-
rection of immune recovery. Thus,
although Moore et al. [1] recommend
HAART initiation at a CD4+ cell count
1350 cells/mL for the most robust immune
recovery, we advocate a broad immuno-
logic investigation of regulatory cytokine
networks to obtain an indication of preth-
erapy immune damage and CD4+ cell res-
cue potential, as well as possible clinical
relapses.
As an example of the exploitation of
g-chain cytokine kinetics, we would like
to share our experience with the IL-7 and
IL-7R system [10] in a cohort of 18 an-
tiretroviral-naive, HIV-positive patients
with advanced infection (nadir CD4+ cell
count, !150 cells/mL) whom we observed
prospectively for the first 12 months of
HAART. These patients displayed different
virological and immunological responses
to HAART: 12 patients had concordant
responses (HIV RNA level, 50 copies/
mL; CD4+ cell count,200 cells/mL), and
6 patients had discordant responses (HIV
RNA level, 50 copies/mL; CD4+ cell
count, 200 cells/mL). Despite having a
higher median baseline plasma IL-7 level
than that for patients with concordant re-
sponses, patients with discordant re-
sponses had a tendency toward reduced
CD4+ cell count and lower IL-7Ra avail-
ability, which, by indicating free IL-7
mainly resulting from receptor down-
modulation rather than compensatory
production, also rules out a functional po-
tential on T cell homeostasis. In fact, dur-
ing HAART, despite a progressive reduc-
tion in IL-7, only patients with concordant
responses displayed a substantial increase
in CD4+ cell and IL-7Ra expression. These
findings, by clearly pointing to opposite
IL-7 and IL-7R dynamics, also indicate
that a lack of IL-7 and IL-7R regulatory
control over CD4+ cell homeostasis could
be the basis of discordant responses, which
cautions against IL-7–based treatment.
In conclusion, it is time to investigate
the early integration of classic quantitative
determinations of CD4+ cell count nadir
proposed by Moore et al. [1] with addi-
tional qualitative measures of CD4+ cell
count nadir–associated immune imbal-
ances. The effort should be to highlight
the immunological role of CD4+ cell count
nadir, not only as a quantitative reflection
of T cell depletion, but mainly as evidence
of more-complex T cell qualitative im-
pairment. The intriguing hypothesis that
a lack of IL-7– and IL-7R–mediated reg-
ulatory function is behind discordant re-
sponses in antiretroviral-naive patients
with advanced infection clearly indicates
the complexity of the immunopathoge-
netic mechanisms of CD4+ cell immune
recovery. The possibility of monitoring
major T cell homeostasis regulators, such
as g-chain cytokines, by possibly disclos-
ing upstream breakdown offers the ap-
pealing prospect of targeted immune
interventions.
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To the Editor—The cover of the 1 Sep-
tember 2007 issue of Clinical Infectious
Diseases shows a 14th-century painting
based on an 11th-century Arabic book
that was described as an illustration of a
treatment of cholera. However, there is no
evidence that the disease that we now call
cholera, caused by Vibrio cholerae, existed
in Europe or Arabia at those times. The
first evidence of the presence of this dis-
ease spreading westward outside the In-
dian subcontinent arose in the early 19th
century [1].
Prior to the emergence of what we now
know as cholera, the term “cholera” was
sometimes applied to what were then con-
sidered to be various disorders traceable
to disturbances of bile, including a “chol-
eric” or angry disposition [2]. It appears
to be likely that the cover illustration was
intended to show treatment of that dis-
order, because the patient appears to be
agitated, with breasts exposed, and seems
to be biting a towel. There is no sign of
the diarrhea, vomiting, dehydration, or
collapse that are associated with what we
now know as cholera.
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Variability of Mumps Viruses
To the Editor—We would like to con-
gratulate Peltola et al. [1] on their excellent
review. As the authors emphasize, protec-
tion from clinical disease is not perfect,
even after 2 doses of mumps component
vaccine; both primary and secondary vac-
cine failure were discussed as potential rea-
sons. Another possibility for lack of pro-
tection after mumps vaccination (and
wild-type virus infection) is the existence
of heterologous mumps viruses that may
escape immune protection because of in-
terstrain antigenic variability [2, 3]. Here,
we report 3 such laboratory-confirmed
cases of symptomatic mumps virus infec-
tion in patients with documented pre-ex-
isting immunity.
The first case occurred in a 12-year-old
girl who had received 2 mumps vaccina-
tions (with Jeryl-Lynn vaccine strain in
both July 1990 and April 1997) and pre-
sented with a lymphadenitis colli. At that
time, antimumps IgG antibodies were de-
termined in a serum specimen (IgG an-
tibody concentration, 1400 IU/mL; IgM
antibody negative). Two weeks later, bi-
lateral parotid swelling appeared; a second
ELISA performed in the same laboratory
revealed a 17-fold increase in antimumps
IgG antibody concentration to 24,000 IU/
mL (IgM antibody negative).
The second case occurred in a 9-year-
old boy who had received 2 documented
mumps vaccinations (with Rubini vaccine
strain in July 1995 and with Jeryl-Lynn
vaccine strain in March 2000) and pre-
sented with acute bilateral parotid swell-
ing; his antimumps IgG antibody concen-
tration was 2900 IU/mL (IgM antibody
negative). Four weeks later, convalescent-
phase serologic examination revealed a
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5.5-fold increase in antimumps IgG an-
tibody concentration to 16,000 IU/mL.
The third case occurred in a 30-year-
old male pediatric resident with no history
of mumps vaccination who had mumps
disease during childhood. He had an an-
timumps IgG antibody concentration of
33 IU/mL in a serum sample obtained for
screening for newly employed health care
workers at our institution. One year later,
the patient developed acute bilateral pa-
rotid swelling. Examination of a serum
sample obtained at that time revealed an
8.5-fold increase in IgG antibody concen-
tration to 277 IU/mL; this sample was
tested together with the previous sample
and was antimumps IgM antibody nega-
tive. Neutralizing assays confirmed rein-
fection, despite pre-existing neutralizing
antimumps serum antibodies. Ten days
later, the patient’s 26-year-old female part-
ner (with no history of mumps disease or
vaccination) developed a primary mumps
infection (IgM antibody positive). These
cases illustrate that symptomatic mumps
reinfection may occur in the presence of
pre-existing specific mumps virus serum
antibodies.
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Diarrhea: A Call to
Reconvene
To the Editor—More than 40 years have
passed since the initial reports of traveler’s
diarrhea (TD), and much has been learned
about the epidemiology of this illness,
which is most often attributed to coloni-
zation of the intestinal track with patho-
genic bacteria of a broad variety [1, 2].
Although our understanding has im-
proved and effective treatment has been
made available, individuals are still trav-
eling from developed countries to lesser
developed countries, and ∼1 of 3 will ex-
perience an acute illness; some of these
individuals will be incapacitated, but most
will improve within a few days [3].
In addition, 150 years ago, the initial
descriptions of postinfectious functional
bowel disorders were reported [4, 5], and
in the past decade, a proliferation of stud-
ies summarized in 2 recent systematic re-
views have concluded that ∼1 of 10 people
who develop TD will acquire postinfec-
tious irritable bowel syndrome (PI-IBS),
despite normal preexisting bowel habits
[6, 7]. Although PI-IBS is perhaps not as
debilitating as less frequent sequelae of re-
active arthritis [8], Guillain Barre´ syn-
drome [9], or inflammatory bowel disease
[10], the attributable burden of PI-IBS is
measurable. A quick calculation reveals
that, among the 100 million travelers each
year from industrialized countries who are
at intermediate to high risk of diarrhea,
∼30 million will develop TD, and 3 mil-
lion new cases of PI-IBS will arise [11].
PI-IBS has been reported to persist in 57%
of patients 6 years after its onset in one
study, and postinfectious functional bowel
disorders (predominantly PI-IBS) per-
sisted in 76% of patients 5 years after its
onset in another study [12, 13]. These ill-
nesses not only decrease the quality of life
of those afflicted, but the economic impact
is considerable. In a review of 18 economic
studies conducted in the United States and
the United Kingdom, the direct cost per
patient-year was estimated to be US$348–
$8750 (in 2002), the annual number of
lost days of work was 9–22 days, and the
indirect cost per patient-year was esti-
mated to be $355–$3344 [14]. Unques-
tionably, this represents significant social
and economic impact.
In addition to travel-related PI-IBS, the
fraction of cases of IBS secondary to do-
mestically acquired foodborne illness
needs to be considered. IBS is the most
common chronic medical illness, seen in
up to 15% of the US population and ac-
counting for nearly one-third of all costs
in gastroenterology as a result of investi-
gation, management, and work loss
among those seeking care [15–17]. Al-
though the attributable fraction of IBS
cases caused by domestic foodborne illness
is unknown, it is likely to be large, given
the frequency of these illnesses [18]. Thus,
the traditional thought of foodborne ill-
ness as a self-limited condition also needs
serious reconsideration and should inform
future food security policy decisions.
Finally, shortly after the first reports of
TD 40 years ago, reports of studies eval-
uating agents for use in prophylaxis fol-
lowed. A number of effective regimens
have been described; however, widespread
use of prophylaxis, particularly antimicro-
bial agents, has been discouraged—a po-
sition formalized in a 1985 National In-
stitutes of Health consensus meeting that
has been unchallenged [19]. We feel that
PI-IBS is a development that challenges
this consensus.
The balance of chemoprophylaxis risk,
compared with the consequences of TD
and sequelae, needs reassessment. Al-
though certain questions remain regarding
the natural history of PI-IBS, effective
treatment, and consequences of chemo-
prophylaxis, it is time that the questions
regarding what can be done to prevent TD
152 • CID 2008:46 (1 January) • CORRESPONDENCE
and who could benefit from preventive
interventions are reconsidered.
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